| ||
| MediciNova asthma drug fails trial; shares crash Reuters MediciNova, which is testing MN-221 as a treatment for acute asthma attacks not responsive to standard therapy, said the drug failed to show a statistically significant improvement over a placebo. MN-221 looks to treat the condition by bypassing ... See all stories on this topic » | ||
| MediciNova dives on asthma study results MarketWatch BOSTON (MarketWatch) -- Shares of MediciNova Inc. (US:mnov) dove 46% to $1.50 Thursday, the day after it reported that a Phase II clinical study for its drug MN-221 failed to show it was effective in treating certain symptoms of acute asthma attacks. See all stories on this topic » | ||
| MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma ... MarketWatch (press release) MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in ... See all stories on this topic » | ||
| MediciNova Misses Primary Goal in Mid-Stage Trial of IV Asthma Drug Xconomy As I reported recently, MediciNova has been developing the compound to treat acute asthma attacks that are not responsive to standard therapy. So shareholders registered their disappointment in preliminary results that MediciNova released today after ... See all stories on this topic » | ||
| MediciNova study doesn't yield significant results MarketWatch The company said patients with acute exacerbations of asthma who were treated with MN-221 in the trial did not see statistically significant improvement in forced expiratory volume in one second, compared to the placebo group. See all stories on this topic » | ||
| Your Health: Asthma action plan necessary San Lorenzo Valley Press-Banner Experiencing exposure to secondhand smoke or other airborne pollution. Treatment of asthma can be broken down into two categories. First, for quick relief, a drug called albuterol is the mainstay of treating an acute attack — one that is happening now. See all stories on this topic » | ||
| MediciNova shares crash after lead asthma drug fails IIb trial FierceBiotech MediciNova's ($MNOV) shares crashed after the San Diego-based biotech said its Phase IIb study of an acute asthma drug failed to hit the primary endpoint. And while the CEO tried to put the data in context, offering reasons for optimism for a planned ... See all stories on this topic » | ||
| Asthma Drug From MediciNova Fails Trial, Stocks Plummet The Inquisitr The latest trial by the biopharmaceutical company has shown that the drug is no more effective than a placebo at treating acute asthman attacks, according to Reuters. MN-221 is supposed to treat acute asthma attacks by bypassing constricted airways, ... See all stories on this topic » |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment